Neutralization of Virus

  • Jane McKeating
Part of the Methods in Molecular Biology book series (MIMB, volume 8)


Viral-specific antibodies of any class that bind to particular epitopes on the surface protein of a virion are capable of neutralizing the infectivity of the virion. Classical neutralization results when antibody binds to the virion and thereby prevents infection of a susceptible cell. The mechanisms of virus neutralization are not fully understood. Neutralization is not simply a matter of coating the virion with antibody, nor indeed of blocking attachment to the host cell. In fact, neutralized virions generally bind to their receptor on susceptible cells (1,2). The block to infection may occur at any point following adsorption and entry: Studies on the neutralization of influenza virus have shown that its neutralization by certain monoclonal antibodies is not mediated through inhibition of attachment, penetration, uncoating, or transport of the viral genome to the nucleus (3), illustrating the complexity of virus neutralization.


Human Immunodeficiency Virus Quantitative Assay Virus Neutralization Susceptible Cell Quantal Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Highlander, S. L., Cai, W. H., Person, S., Levine, M, and Glorioso, J. C. (1988) Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration. J. Virol. 62, 1881–1888.PubMedGoogle Scholar
  2. 2.
    Iinsley, P.S., Ledbetter, J.A., Kinney-Thomas, E, and Hu, S. L (1988) Effects of antigp120 monoclonal antibodies on CD4 receptor binding by the env protein of HIV-1. J. Virol. 62, 3695–3702.Google Scholar
  3. 3.
    Taylor, H. P. and Dimmock, N. J (1985) Mechanisms of neutralization of influenza virus by 1gM. J. Gen. Vīrol. 66, 903–907.CrossRefGoogle Scholar
  4. 4.
    Zagury, D., Bernard, J., Cheynier, R., Desportes, I., Leonard, R., Fouchard, M, Reveil, B., Ittele, D., Lurhuma, Z., Mbayo, K., Wane, J., Salaun, J., Goussard, B., Dechazal, L, Burny, A, Nara, P., and Gallo, R. C. (1988) A group-specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 332, 728–731.PubMedCrossRefGoogle Scholar
  5. 5.
    Chesebro, B. and Wehrly, K. (1988) Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62, 3778,3779.Google Scholar
  6. 6.
    Harada, S., Purtilo, D., Koyanagi, K., Sonnabend J., and Yamamoto, N. (1986) Sensitive assay for neutralizing antibodies against AIDS-related viruses. J. Immunol. Meth. 92, 177–181.CrossRefGoogle Scholar
  7. 7.
    Montefiori, D. C., Robinson, W. E., Schuffman, S. S., and Mitchell, W. M (1988) Evaluation of anti-viral drugs and neutralising antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26,231–235.PubMedGoogle Scholar
  8. 8.
    Popovic, M., Sarngadharan, M. G., Read, E., and Gallo, R. C. (1984) A method for detection, isolation, and continuous production of cytopathic human T-lymphotropic retroviruses of the HTLV family from patients with AIDS and pre-AIDS. Science 224, 493–500.CrossRefGoogle Scholar
  9. 9.
    Harada, S., Koyanagi, Y., and Yamamoto, N. (1985) Infection of HTLV-III/LAV in HTLV-I carrying MT2 and MT4 and application in a plaque assay. Science 229, 563–566.PubMedCrossRefGoogle Scholar
  10. 10.
    Sodroski, J. G., Rosen, C. A., and Haseltine, W. A. (1984) Trans-acting transcriptional activation of the long terminal repeat of human T-lymphotropic viruses in infected cells. Science 225, 381–385.PubMedCrossRefGoogle Scholar
  11. 11.
    McKeating, J. A., McKnight, A., McIntosh, K., Clapham, P. R., Mulder, C., and Weiss, R. A. (1989) Evaluation of human and simian immunodeficiency virus plaque and neutralization assays. J. Gen Virol 70, 3327–3333.PubMedCrossRefGoogle Scholar

Copyright information

© The Humana Press Inc., Clifton, NJ 1991

Authors and Affiliations

  • Jane McKeating
    • 1
  1. 1.Chester Beatty LaboratoriesInstitute of Cancer ResearchLondonUK

Personalised recommendations